|
|
|
|
|
Pegfilgrastim
drug data and news
Pegfilgrastim drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Pegfilgrastim | ||
| Brand Names/Synonyms | Granulocyte colony-stimulating factor precursor;G-CSF;Pluripoietin;Filgrastim;Lenograstim; Neulasta (Amgen Inc.) | ||
| Indication | Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant | ||
| Sponsored links | Description | PEGylated (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation. | |
| Pharmacology | Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim. | ||
| Mechanism Of Action | Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase | ||
| Pegfilgrastim News (When available) |
Research and Markets: Aranesp, Neulasta and Enbrel have all Shown ... 16 May 2006 Dose-Dense Therapy for NHL Safely Administered with Support of ... Apr 18, 2006 Dose-Dense Adjuvant Chemotherapy for Node-Positive Breast Cancer ... May 5, 2006 Amgen's First Quarter 2006 Adjusted Earnings per Share, Excluding ... Apr 20, 2006 Further Evidence that Chemotherapy-Induced Neutropenia Results in ... Apr 17, 2006 | ||
| Dosage Forms | SOLUTION | ||
| Drug_Category | Immunomodulatory Agents; Anti-infective Agents; Antineutropenic Agents; hematopoietic agents (20:16.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | PEGylated human granulocyte colony stimulating factor | ||
| Chemical Formula | C845H1343N223O243S9 | ||
| Molecular Weight | 18802.8 | ||
| Smiles String | Not Available | ||
| Melting Point | 60 oC (Luo, P., Protein Science 11:1218-1226 (2002)) | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | 0.209 | ||
| Isoelectric Point | 5.65 | ||
| Biotransformation | Not Available | ||
| Half Life | 15-80 hrs | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Pegfilgrastim.html http://www.rxlist.com/cgi/generic3/neulasta.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00094 | ||
| CAS Registry Number | 208265-92-3 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10809 | ||
| SwissProt ID | CSF3_HUMAN (P09919) | ||
| GenBank ID | X03438 | ||
| Drug ID Number [DIN] | 2249790 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |